scholarly journals The dual glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 receptor agonist tirzepatide improves cardiovascular risk biomarkers in patients with type 2 diabetes: A p ost hoc analysis

2021 ◽  
Author(s):  
Jonathan M. Wilson ◽  
Yanzhu Lin ◽  
M. Jane Luo ◽  
Gary Considine ◽  
Amy L. Cox ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Cardiovascular Risk ◽  
Receptor Agonist ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1 ◽  
Risk Biomarkers

scholarly journals Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes

2008 ◽  
Vol 25 (9) ◽  
pp. 1129-1131 ◽  
Author(s):  
J.-P. Courrèges ◽  
T. Vilsbøll ◽  
M. Zdravkovic ◽  
T. Le-Thi ◽  
T. Krarup ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Cardiovascular Risk ◽  
Once Daily ◽  
Beneficial Effects ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1 ◽  
Risk Biomarkers

938-P: The Relationship between Timing of Initiation on a Glucagon-Like Peptide-1 Receptor Agonist and HbA1c among Patients with Type 2 Diabetes

Diabetes ◽  
2020 ◽  
Vol 69 (Supplement 1) ◽  
pp. 938-P
Author(s):  
RALEIGH E. MALIK ◽  
REEMA MODY ◽  
MAUREEN J. LAGE ◽  
KRISTINA BOYE
Keyword(s):  
Type 2 Diabetes ◽  
Receptor Agonist ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1 ◽  
Timing Of Initiation ◽  
The Relationship

scholarly journals Glucagon-Like Peptide 1 Receptor Agonist (GLP1RA) Exposure and Outcomes in Type 2 Diabetes: A Systematic Review of Population-Based Observational Studies

2021 ◽  
Author(s):  
Thomas M. Caparrotta ◽  
Jack B. Templeton ◽  
Thomas A. Clay ◽  
Sarah H. Wild ◽  
Rebecca M. Reynolds ◽  
...  
Keyword(s):  
Systematic Review ◽  
Type 2 Diabetes ◽  
Observational Studies ◽  
Receptor Agonist ◽  
Population Based ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1

scholarly journals Insulin/Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy for the Treatment of Type 2 Diabetes: Are Two Agents Better Than One?

2018 ◽  
Vol 36 (2) ◽  
pp. 138-147 ◽  
Author(s):  
Vanita R. Aroda ◽  
Joseph R. Arulandu ◽  
Anthony J. Cannon
Keyword(s):  
Type 2 Diabetes ◽  
Combination Therapy ◽  
Receptor Agonist ◽  
Two Agents ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1 ◽  
Better Than

scholarly journals Potential cardiovascular benefits of GLP-1 analogues: evidence and implications for type 2 diabetes management

2020 ◽  
pp. 24-29
Author(s):  
M Vally
Keyword(s):  
Type 2 Diabetes ◽  
Cardiovascular Risk ◽  
Paradigm Shift ◽  
Diabetes Management ◽  
Clinical Trial Data ◽  
Sglt2 Inhibitors ◽  
Atherosclerotic Cardiovascular Disease ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1

Glucagon-like peptide-1 (GLP-1) analogues are an injectable therapy used in the management of type 2 diabetes. These drugs seem to reduce cardiovascular risk factors and clinical trial data seems to suggest that liraglutide and semaglutide reduce cardiovascular risk in patients with type 2 diabetes and concomitant atherosclerotic cardiovascular disease. The search for agents such as these (and SGLT2 inhibitors) that not only manage diabetes but also reduce cardiovascular risk has resulted in a paradigm shift in the way diabetes can be managed.

The good companions: insulin and glucagon-like peptide-1 receptor agonist in type 2 diabetes. A systematic review and meta-analysis of randomized controlled trials

2019 ◽  
Vol 154 ◽  
pp. 101-115 ◽  
Author(s):  
Maria Ida Maiorino ◽  
Paolo Chiodini ◽  
Giuseppe Bellastella ◽  
Lorenzo Scappaticcio ◽  
Miriam Longo ◽  
...  
Keyword(s):  
Systematic Review ◽  
Type 2 Diabetes ◽  
Randomized Controlled Trials ◽  
Receptor Agonist ◽  
Meta Analysis ◽  
Controlled Trials ◽  
Randomized Controlled ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1

Effects of 6 months glucagon-like peptide-1 receptor agonist treatment on endothelial function in type 2 diabetes mellitus patients

2013 ◽  
Vol 15 (8) ◽  
pp. 770-773 ◽  
Author(s):  
N. D. Hopkins ◽  
D. J. Cuthbertson ◽  
G. J. Kemp ◽  
C. Pugh ◽  
D. J. Green ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Endothelial Function ◽  
Receptor Agonist ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1
Sign in / Sign up

Export Citation Format

Share Document